National MS Society: Negative Results of High Dose Biotin Clinical Trial Published
October 30, 2020
October 30, 2020
NEW YORK, Oct. 30 (TNSJou) -- The National Multiple Sclerosis Society issued the following news:
A large Phase 3 clinical trial of high-dose Biotin (MD1003(R)) in people with progressive MS failed to reverse disability or improve walking speed. The results, originally announced by MedDay Pharmaceuticals in March 2020, have now been published. Treatment with biotin led to inaccurate laboratory tests for other health conditions. The authors conclude that MD1003 or commercially availab . . .
A large Phase 3 clinical trial of high-dose Biotin (MD1003(R)) in people with progressive MS failed to reverse disability or improve walking speed. The results, originally announced by MedDay Pharmaceuticals in March 2020, have now been published. Treatment with biotin led to inaccurate laboratory tests for other health conditions. The authors conclude that MD1003 or commercially availab . . .